Ibrutinib CAS 936563-96-1 Maʻemaʻe >99.5% (HPLC) API

ʻO ka wehewehe pōkole:

Inoa Kemika: Ibrutinib

CAS: 936563-96-1

Maʻemaʻe: >99.5% (HPLC)

ʻAno: Keʻokeʻo a i ʻole-White Crystal Powder

ʻO Ibrutinib kahi mea hoʻopale BTK i hoʻohana ʻia e mālama i ka Chronic Lymphocytic Leukemia (CLL) a me Mantle Cell Lymphoma (MCL)

Hoʻokaʻaʻike: Kauka Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

E hoʻouna i ka leka uila iā mākou

Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Ibrutinib pili i waena:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Na Waiwai Kemika:

Inoa Kimia	Ibrutinib
Nā huaʻōlelo like	1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- ʻekahi;PCI-32765
Helu CAS	936563-96-1
Kūlana Kūʻai	Ma ka waihona, hoʻonui ʻia a hiki i nā tona
ʻĀpana Molekala	C25H24N6O2
Kaumaha Molecular	440.50
Brand	Kemika Ruifu

Nā kikoʻī:

'ikamu	Nā kikoʻī
Ka nana aku	Keʻokeʻo a i ka pauka kristal keʻokeʻo
ʻIkepili	IR;HPLC
Nalo ma ka maloo	<0.50%
Koena ma ka Ignition	≤0.10%
Nā Metala Kaumaha (e like me Pb)	≤20ppm
ʻO kēlā me kēia haumia hoʻokahi	≤0.20%
Huina paumaele	<0.50%
Maʻemaʻe / Kaʻina Hanana	>99.5% (HPLC)
Kūlana hoʻāʻo	Kūlana ʻoihana
Hoʻohana	API

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.

Pono:

FAQ:

Noi:

ʻO Ibrutinib (CAS: 936563-96-1) kahi mea hoʻopale o Bruton tyrosine kinase (BTK) no ka mālama ʻana i ka maʻi maʻi lymphocytic maʻi (CLL) a me ka lymphoma cell mantle (MCL).ʻO ka MCL a me ka CLL no ka lymphoma non-Hodgkin B-cell, ʻo ia ka refractory a hiki ke hoʻi hou.ʻAʻole i manaʻo ʻia ka chemoimmunotherapy i hoʻohana mau ʻia, a ʻo ka papa 3 a i ʻole 4 mau hopena ʻino ke kū pinepine ʻia.Hiki i ka Ibrutinib ke hui pū me BTK, ka mea e pono ai no ka hoʻokumu ʻana, ka ʻokoʻa, kamaʻilio a me ke ola ʻana o nā lymphocytes B, a me ka pale ʻole ʻana i ka hana o BTK, e pale pono i ka hoʻonui ʻana a me ke ola ʻana o nā pūnana maʻi.Eia kekahi, ua komo koke ia ma hope o ka hoʻoponopono waha, ua hiki ke kiʻekiʻe o ka plasma kiʻekiʻe i ka 1 ~ 2h, a ʻo nā hopena maikaʻi ʻole he papa 1 a i ʻole 2, e lilo ia i koho hou no ka mālama ʻana iā CLL a me MCL.Ma Nowemapa 13, 2013, ka US FDA e hoʻolalelale i ka hui ʻo Johnson & Johnson i ʻāpono ʻia a me ʻAmelika Hui Pū ʻIa ʻo Imbruvica (inoa maʻamau: Ibrutinib) no ka mālama ʻana i ka lymphoma cell mantle (MCL).Ua hāʻawi ʻia ʻo Ibrutinib i ke kūlana Therapy breakthrough e ka FDA i Pepeluali 2013 a ua ʻae ʻia no MCL ma Nowemapa 13, 2013 a me CLL ma Pepeluali 12, 2014, kēlā me kēia.